Article

Avedro, Inc., company update: Epi-on crosslinking (CXL) and PiXL technology

Author(s):

Julianne Mobilian
Conferences|ASCRS

ICYMI: Here's what's in the 2019 pipeline

Rajesh Rajpal, MD, Chief Medical Officer of Avedro, Inc., provides a company update on Epi-on crosslinking (CXL) and PiXL technology during the 2019 ASCRS conference in San Diego.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
(Image credit: Ophthalmology Times) ASCRS 2025: Eric D. Donnenfeld, MD, on the effect of lifitegrast clinical signs and biomarkers in dry eye disease
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
Related Content
Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
July 21st 2025

Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Cloudbreak Pharma reports positive phase 2 results for CBT-004 in vascularized pinguecula
July 21st 2025

Cloudbreak Pharma reports positive phase 2 results for CBT-004 in vascularized pinguecula

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain
July 18th 2025

OKYO Pharma announces positive results from phase 2 trial of urcosimod for neuropathic corneal pain

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis
July 14th 2025

Krystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitis

© 2025 MJH Life Sciences

All rights reserved.